REMEGEN(SH:688331) Donghai Securities·2024-11-06 16:49Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company has achieved rapid revenue growth, with a total revenue of 1.209 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 57.10%. The net profit attributable to the parent company was -1.071 billion yuan, a decrease of 3.96% year-on-year [6] - The company’s gross profit margin has significantly improved, reaching 79.75% for the first three quarters of 2024, up by 2.86 percentage points year-on-year. In Q3 alone, the gross profit margin was 82.11%, an increase of 5.86 percentage points year-on-year [6] - The company has a strong cash reserve of approximately 1.12 billion yuan and a loan credit limit of about 2.8 billion yuan, indicating solid financial health [6] Summary by Sections Revenue and Profitability - For Q3 2024, the company reported a revenue of 467 million yuan, a year-on-year increase of 34.60% and a quarter-on-quarter increase of 13.56%. The net profit attributable to the parent company for Q3 was -291 million yuan, showing an 11.08% increase year-on-year and a 32.57% increase quarter-on-quarter [6] - The company’s R&D expense ratio was 95.41% for the first three quarters of 2024, down by 16.09 percentage points year-on-year, while the selling expense ratio was 51.51%, down by 18.64 percentage points [6] Product Development - The NDA for the third indication of Taitasip has been accepted, with the drug now fully approved for SLE in China and undergoing Phase III clinical trials in the US. The drug has also received approval for rheumatoid arthritis in July 2024 and has a listing application for myasthenia gravis accepted in October 2024 [7] - The company is expanding the indications for Vidisizumab in ulcerative colitis (UC), gastric cancer (GC), and breast cancer (BC), with ongoing clinical trials showing positive signals [8] Future Projections - The company is expected to achieve revenues of 1.586 billion yuan, 2.175 billion yuan, and 2.952 billion yuan for 2024, 2025, and 2026 respectively. The net profit attributable to the parent company is projected to be -1.138 billion yuan, -987 million yuan, and -356 million yuan for the same years [8]